SAN FRANCISCO, May 8, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. (PRNewsfoto/Nektar Therapeutics) Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar’s cash and marketable securities are expected to support
Richard Miller Thanks, Leiv, and good afternoon, everyone. Thank you for joining us today for our business update call.As we look into 2025, we remain optimistic on the potential for soquelitinib to provide a powerful new approach for the treatment of a broad range of immune diseases and cancer. Soquelitinib is well-positioned as a first-in-class
Research and Development Expenses (Q4 2024): $6 million, up from $4 million in Q4 2023. Research and Development Expenses (Full-Year 2024): $19.4 million, up from $16.5 million in 2023. Net Loss (Q4 2024): $12.1 million, compared to $6.7 million in Q4 2023. Net Loss (Full-Year 2024): $62.3 million, compared to $27.0 million in 2023. Stock